Search research articles
Contact Us
Filters
Showing results (931-940 of 944) with videos related to
Page
of 95
Sort By:
ACS Central Science
|
April 27, 2026
Detecting Bacteria in Their Mammalian Hosts Using Metabolism-Targeted [<sup>13</sup>C]CO<sub>2</sub> Breath Testing
Marina López-Álvarez, Sang Hee Lee, Anju Wadhwa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 4, 2023
Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group
Ashish M Kamat, Andrea B Apolo, Marek Babjuk, et al.
Nature Ecology & Evolution
|
October 23, 2019
A horizon scan of priorities for coastal marine microbiome research
Stacey M Trevathan-Tackett, Craig D H Sherman, Megan J Huggett, et al.
European Urology
|
April 7, 2026
Pembrolizumab in Combination With Gemcitabine and Concurrent Hypofractionated Radiation Therapy as Bladder-sparing Treatment for Muscle-invasive Urothelial Cancer of the Bladder: A Multicenter Phase 2 Trial
Minas P Economides, Peter H O'Donnell, Ajjai S Alva, et al.
Proceedings. Biological Sciences
|
July 11, 2014
The tropicalization of temperate marine ecosystems: climate-mediated changes in herbivory and community phase shifts
Adriana Vergés, Peter D Steinberg, Mark E Hay, et al.
Bladder Cancer (Amsterdam, Netherlands)
|
July 12, 2024
Advancing Clinical Trial Design for Non-Muscle Invasive Bladder Cancer
Elaine Chang, Noah M Hahn, Seth P Lerner, et al.
Urologic Oncology
|
December 13, 2023
Interruptions in bladder cancer care during the COVID-19 public health emergency
John L Gore, Kristin Follmer, Jason Reynolds, et al.
The Journal of Urology
|
May 5, 2024
Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial
Vikram M Narayan, Stephen A Boorjian, Mehrdad Alemozaffar, et al.
Journal of the Neurological Sciences
|
February 7, 2018
Argentinean recommendations on the identification of treatment failure in relapsing remitting multiple sclerosis patients
Edgardo Cristiano, Ricardo Alonso, Amelia Alvez Pinheiro, et al.
The Lancet. Oncology
|
November 30, 2020
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial
Stephen A Boorjian, Mehrdad Alemozaffar, Badrinath R Konety, et al.
Page
of 95
Search research articles
Search
Showing results (931-940 of 944) with videos related to
Sort By:
Page
of 95
ACS Central Science
|
April 27, 2026
Detecting Bacteria in Their Mammalian Hosts Using Metabolism-Targeted [<sup>13</sup>C]CO<sub>2</sub> Breath Testing
Marina López-Álvarez, Sang Hee Lee, Anju Wadhwa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 4, 2023
Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group
Ashish M Kamat, Andrea B Apolo, Marek Babjuk, et al.
Nature Ecology & Evolution
|
October 23, 2019
A horizon scan of priorities for coastal marine microbiome research
Stacey M Trevathan-Tackett, Craig D H Sherman, Megan J Huggett, et al.
European Urology
|
April 7, 2026
Pembrolizumab in Combination With Gemcitabine and Concurrent Hypofractionated Radiation Therapy as Bladder-sparing Treatment for Muscle-invasive Urothelial Cancer of the Bladder: A Multicenter Phase 2 Trial
Minas P Economides, Peter H O'Donnell, Ajjai S Alva, et al.
Proceedings. Biological Sciences
|
July 11, 2014
The tropicalization of temperate marine ecosystems: climate-mediated changes in herbivory and community phase shifts
Adriana Vergés, Peter D Steinberg, Mark E Hay, et al.
Bladder Cancer (Amsterdam, Netherlands)
|
July 12, 2024
Advancing Clinical Trial Design for Non-Muscle Invasive Bladder Cancer
Elaine Chang, Noah M Hahn, Seth P Lerner, et al.
Urologic Oncology
|
December 13, 2023
Interruptions in bladder cancer care during the COVID-19 public health emergency
John L Gore, Kristin Follmer, Jason Reynolds, et al.
The Journal of Urology
|
May 5, 2024
Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial
Vikram M Narayan, Stephen A Boorjian, Mehrdad Alemozaffar, et al.
Journal of the Neurological Sciences
|
February 7, 2018
Argentinean recommendations on the identification of treatment failure in relapsing remitting multiple sclerosis patients
Edgardo Cristiano, Ricardo Alonso, Amelia Alvez Pinheiro, et al.
The Lancet. Oncology
|
November 30, 2020
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial
Stephen A Boorjian, Mehrdad Alemozaffar, Badrinath R Konety, et al.
Page
of 95